Shenzhen Grandbaybio Development Consulting Co., Ltd. (hereinafter referred to as "Grandbaybio") is jointly formed by the team of Dr. Tian Yuan, the founder and chairman of the Yabuli China Entrepreneurs Forum, and the team of Dr. Zhang Dan, the founder of Kunling Medicine and a foreign academician of the Russian Academy of Engineering. It is a collection of talents and resources from ICH (International Coordination Conference on Drug Registration Technology for Human Use), key opinion leaders in Chinese and foreign industries, cross-border biomedicine investment and intellectual property transactions, clinical development of innovative drugs, park operations, investment and promotion.
Grandbaybio is the operation and management company of Shenzhen Pingshan ICH Biomedical Park. It is responsible for building a comprehensive service platform for the operation of the ICH Biomedical Park and providing comprehensive and complete solutions for the commercial operation of the park.
Raju Kucherlapati is a professor of genetics and medicine at Harvard Medical School in Boston, and a senior geneticist at Brigham and Women's Hospital in Boston and Massachusetts General Hospital.
He received a PhD in genetics from the University of Illinois at Urbana-Champaign, and worked as a postdoctoral fellow at Yale University, and later became a professor of genetics at the University of Illinois School of Medicine. From 1989 to 2001, he served as Professor Saul & Lola Kramer, University Professor, and Dean of the Department of Molecular Genetics at the Albert Einstein School of Medicine in New York. In 2001, he joined Harvard University, established the Harvard University Genetics and Genomics Partner Center, and served as the founding scientific director of the center.
Dr. Kucherlapati's research involves human gene mapping and sequencing, and has participated in the establishment of mouse models used in the American Human Cancer, Human Genome Project, and Cancer Genome Atlas Project. He has published more than 400 original research articles, holds a number of patents, served in the editorial department of the New England Journal of Medicine, and was the editor-in-chief of the journal Genomics. He is a member of the American Association for the Advancement of Science and was elected a member of the National Academy of Medicine.
Dr. Kucherlapati has extensive experience in establishing and assisting in the management of many biotech companies in the United States. He is the founder of Cell Genesys, Abgenix, Millennium Pharmaceuticals, and is currently a member of the board of directors of the listed biopharmaceutical company Puretech Health.
Dr. Kucherlapati is also a firm advocate of "precision medicine" and has co-organized four China Cancer Precision Medicine Conferences.
Dr. Johnson graduated from Harvard University and the University of Minnesota Medical School. His postdoctoral training was at the University of Chicago Hospitals and Clinics and the National Cancer Institute.
In 1992, he became the head of the Department of Lung Cancer Biology, NCI Medical Division, until 1998, he joined Dana-Farber. Dr. Johnson served as the President of the American Society of Clinical Oncology (ASCO) and directed the lung cancer program at Dana-Farber/Harvard Cancer Center. His translational research is devoted to testing the efficacy of new therapeutic agents against lung cancer and other thoracic malignancies with specific genomic changes. Dr. Johnson has received many awards including the American Association for Cancer Research Science Award 2010 and the International Association for Lung Cancer Research Award 2009.